萨诺菲的Sarclisa 获得欧盟批准 多重间皮瘤, 显示提高治疗效果。 Sanofi's Sarclisa gets EU approval for multiple myeloma, shown to boost treatment efficacy.

Sanofi's Sarclisa已得到欧洲委员会的批准,用于治疗用于VRd治疗的符合移植条件的新诊断出多处骨髓瘤。 Sanofi's Sarclisa has been approved by the European Commission for treating transplant-eligible newly diagnosed multiple myeloma when used with VRd therapy. 这项决定是继第三阶段研究结果之后作出的,其结果表明,与VRd相比,在最低限度的残余疾病消极性和无累进性存活率方面有了显著改进。 This decision follows phase 3 study results showing significant improvements in minimal residual disease negativity and progression-free survival compared to VRd alone. 这一批准扩大了Sarclisa在欧盟所有治疗阶段的使用范围。 The approval expands Sarclisa's use across all treatment stages in the EU.